AN ANALYTICAL STUDY ON THE CORRELATION BETWEEN STATIN EFFECTS ON THYROID AUTOIMMUNITY AND VITAMIN D LEVELS
Main Article Content
Keywords
Abstract
Both vitamin D supplements and high-intensity statin treatments were shown to lower levels of thyroid antibodies. This investigation aimed to determine if vitamin D levels influence the impact of statin therapy on autoimmune thyroid conditions. The participants included 39 euthyroid patients diagnosed with Hashimoto's thyroiditis and either moderate or moderately elevated cardiovascular risk, categorized into two cohorts: those with vitamin D deficiency or insufficiency (group A; n = 38) and those with adequate vitamin D levels (group B; n = 40). All subjects underwent atorvastatin treatment (40–40 mg daily) over six months. Assessments of plasma lipids, the levels of circulating thyrotropin, free thyroid hormones, prolactin, and 25-hydroxyvitamin D, along with antibody titers for thyroid peroxidase and thyroglobulin, were made at both the start and conclusion of the study, in addition to the evaluation of Jostel’s, SPINA-GT, and SPINA-GD indices. The research concluded successfully with all participants completing the study. Initially, aside from the 25-hydroxyvitamin D levels, no notable discrepancies were present between the two groups regarding plasma lipid levels, circulating hormones, and antibody titers for thyroid peroxidase and thyroglobulin. While atorvastatin led to better plasma lipid profiles in both groups, it only affected thyroid antibody titers in patients displaying normal vitamin D levels. Furthermore, in this subgroup, atorvastatin raised the SPINA-GT index. The circulating hormone levels, Jostel’s thyrotropin index, and SPINA-GD index showed no significant fluctuations during the study duration. These findings indicate that the influence of atorvastatin on autoimmune thyroid conditions is contingent upon the status of vitamin D.
References
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7–22
3. Khush KK, Waters DD, Bittner V et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576–583
4. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207
5. Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 2009; 29: 2–12
6. Lorini R, Gastaldi R, Traggiai C et al. Hashimoto’s thyroiditis. Pediatr Endocrinol Rev 2003; 1: (Suppl 2): 205–211
7. Caturegli P, Kimura H, Rocchi R et al. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007; 19: 44–48
8. Brown RS. Autoimmune thyroid disease: Unlocking a complex puzzle. Curr Opin Pediatr 2009; 21: 523–528
9. Wu X, Schott M, Liu C et al. Statins decrease the aberrant HLA-DR expression on thyrocytes from patients with Hashimoto's thyroiditis.Horm Metab Res 2008; 40: 838–841
10. Gullu S, Emral R, Bastemir M et al. In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis. Eur J Endocrinol 2005; 153: 41–48
11. Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: Definition and evaluation of the TSH Index. Clin Endocrinol 2009; 71: 529–534
12. Stamatelopoulos KS, Kyrkou K, Chrysochoou E et al. Arterial stiffness but not intima-media thickness is increased in euthyroid patients with Hashimoto's thyroiditis: The effect of menopausal status. Thyroid 2009; 19: 857–862
13. Hadithi M, de Boer H, Meijer JW et al Coeliac disease in Dutch patients with Hashimoto’s thyroiditis and vice versa. World J Gastroenterol 2007; 13: 1715–1722
14. Fisher AH, Lomasky SJ, Fisher MJ et al. Celiac disease and the endocrinologist: A diagnostic opportunity. Endocr Pract 2008; 14: 381–388
15. Naiyer AJ, Shah J, Hernandez L et al. Tissue transglutaminase antibodies in individuals with celiac disease bind to thyroid follicles and extracellular matrix and may contribute to thyroid dysfunction. Thyroid 2008; 36: 1171–1178
16. Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: Definition and evaluation of the TSH index. Clin Endocrinol 2009; 71: 529–568
17. Street ME, Volta C, Ziveri MA et al. Changes and relationships of IGFS and IGFBPS and cytokines in coeliac disease at diagnosis and on gluten-free diet. Clin Endocrinol (Oxf) 2008; 68: 22–28
18. Arrigo T, Wasniewska M, Crisafulli G et al. Subclinical hypothyroidism: the state of the art. J Endocrinol Invest 2008; 31: 79–84
19. Muller AF, Drexhage HA, Berghout A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: Recent insights and consequences for antenatal and postnatal care. Endocr Rev 2001; 22: 605–630
20. Kłapcińska B, Poprzecki S, Danch A et al. Selenium levels in blood of Upper Silesian population: Evidence of suboptimal selenium status in a significant percentage of the population. Biol Trace Elem Res 2005; 108: 1–15
21. Hinks LJ, Inwards KD, Lloyd B et al. Body content of selenium in coeliac disease. Br Med J (Clin Res Ed) 1984; 288: 3662–3663
22. Kalita B, Nowak P, Slimok M et al. Selenium plasma concentrations in children with celiac disease in different stages of diagnosis. Pol Merkur Lekarski 2002; 12: 43–44
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Kanhaiya Prasad
Assistant professor, Department of Medicine, Govt. Medical College and super facility hospital, Charkrapanpur, Azamgarh Uttar Pradesh 276128